Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study - Wikidata - thesis-toulmin - TriplyDB

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

http://www.wikidata.org/entity/Q24645376

about

Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study Cardiovascular risk stratification in familial hypercholesterolaemia The genetics and screening of familial hypercholesterolaemia Familial hypercholesterolemia: present and future management Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology An online questionnaire survey of UK general practitioners’ knowledge and management of familial hypercholesterolaemia Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia The panorama of familial hypercholesterolemia in Latin America: a systematic review.Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia Familial hypercholesterolemia: A review Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study Do statins reduce the incidence of stroke in familial hypercholesterolemia?The UCL low-density lipoprotein receptor gene variant database: pathogenicity update Cascade Screening for Familial Hypercholesterolemia (FH)Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations Familial hypercholesterolemia: developments in diagnosis and treatment Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010.Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia?Identification of Medically Actionable Secondary Findings in the 1000 Genomes.A model of care for familial hypercholesterolaemia: key role for clinical biochemistry.A novel mutation (Cys308Phe) of the LDL receptor gene in families from the South-Eastern part of Poland Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.Acute Myocardial Infarction in a 26-Year-Old Patient With Familial Hypercholesteremia Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.The genetic spectrum of familial hypercholesterolemia in Pakistan Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype.Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs?Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study.Identification and management of familial hypercholesterolaemia: what does it mean to primary care?Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia.Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics.Utility of genetic determinants of lipids and cardiovascular events in assessing risk.LDL apheresis and inflammation--implications for atherosclerosis.Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes.

P2860

Q24658655-35E78C7D-347E-4B97-BF1B-75E4311651C9 Q26749104-8246A452-9525-41B0-856D-ACC6860E3835 Q26753081-0BBCFB83-02E2-44B6-964E-B73ECAD6B8F4 Q26828489-144BB8CB-8C63-4544-A6D9-087A3954D47B Q26828780-8AB53065-C032-4C43-B6D9-7F3D8745D7A4 Q26866033-96AF3DDA-C10F-4127-B635-95F08194D316 Q28591611-8C1B0DCA-E451-48B2-AD76-F56DC79F573B Q28716905-8CCBEDB5-BC18-4CE7-BA56-934806E96620 Q30244116-8B85C58B-6BBE-4325-B386-0CEBA12FCE16 Q33642312-8045C11F-FE70-4828-9A72-587221FFEF58 Q33803782-96A9C52A-C419-4889-AD71-0465E7C43D2B Q33818871-45847170-0C8E-4579-BD3B-CD2AF225C6AD Q33851411-9FDF5C21-E969-4CFB-9558-AC50D9E1F6EA Q33856286-450B09B4-1FF8-4B9F-9350-C5D9481B6E6E Q33886208-638F8958-777E-4D10-AEC5-42DEBC5BA10C Q33919782-20ECB327-1DCC-48D6-970A-34368EE9EE4D Q33956413-CFD8F31C-7B5F-41B2-97CC-CBC705EE06FF Q34106665-0B3D01FA-B585-473B-966B-950EB2572A55 Q35114991-DBC252F1-8CBD-41AD-80E7-E13EA1C636A1 Q35121832-C9081E23-8BA4-472D-948D-296B4C9D917F Q35217153-7CE0FF5F-1693-4F49-863D-7454C7A871AC Q35762437-D5653FAB-EC67-439B-A513-D24C87600130 Q35771729-958F7559-CF6F-44C7-B0AC-6C818F1B51F3 Q35848502-DC5D969B-46FC-45C8-B1D4-2C11C803D1CE Q36035727-8792413E-E6AB-49E3-8ADF-9CF1E825E77C Q36130225-E600E46E-B734-4E20-9168-51AAF294EAF9 Q36339537-BBA4A2EE-484E-4DC5-8BDE-BA4292C81FF4 Q36971698-B413731D-F0E7-49DA-8424-946F670D1DA3 Q36983486-66FAAFE1-6959-404E-8E5B-0877397B81AE Q36983501-D2D9AF61-FBEE-4804-8937-47AD23FA73F1 Q37066247-EF9FAF95-2B04-41AA-A858-7E76621B115E Q37069579-919EF401-0773-488D-B56C-968B0931D1BD Q37082508-F621EA97-DC3F-46EB-87D0-7FFB2C726495 Q37362738-C9C0D3E5-70A6-4036-9357-67197EA28B62 Q37398099-9F45844E-23ED-4AC1-95E1-897AF3FB0B2D Q37584256-05927BDE-84A4-44B6-A93F-462D4DE05379 Q37723246-45797672-E8CD-4C10-BC38-E69F2E480269 Q37842125-47E1D19C-6F92-46AF-A9B6-F2474CE528CE Q38016475-22A1513A-50F6-438A-B9DD-FCB944A0D0E7 Q38087382-89AE6AF3-657C-42EC-B337-B13EDFE24465

P2860

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

http://www.wikidata.org/entity/Q24645376

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Reductions in all-cause, cance ...... : a prospective registry study

@ast

Reductions in all-cause, cance ...... : a prospective registry study

@en

Reductions in all-cause, cance ...... : a prospective registry study

@nl

type

label

Reductions in all-cause, cance ...... : a prospective registry study

@ast

Reductions in all-cause, cance ...... : a prospective registry study

@en

Reductions in all-cause, cance ...... : a prospective registry study

@nl

prefLabel

Reductions in all-cause, cance ...... : a prospective registry study

@ast

Reductions in all-cause, cance ...... : a prospective registry study

@en

Reductions in all-cause, cance ...... : a prospective registry study

@nl

P1433

Q24645376-0783C46B-C9E7-4231-97DA-2042F26D5E66

P1476

Q24645376-6CC039BC-C5FD-45E0-8F16-A4ADC6018E7A

P2093

Q24645376-2254E308-0BA7-4DA9-ACAA-51E1B83E1332

Q24645376-35F7E81B-A1EC-4917-B182-549D80C15969

Q24645376-7AA3824A-967A-4295-86B8-D129BB7D4241

Q24645376-B9317DFB-A628-4B0A-B104-7C25D9E155CC

Q24645376-BA51D423-95A2-4ED6-81E3-52DAD7164153

Q24645376-DA974F09-2F75-43EB-8C5F-A7535EC9C14C

Q24645376-E67A8747-BF94-47F3-8EDA-01F65C83D26F

P2860

Q24645376-01CBAD42-B714-49EF-A1F0-13E70C53260C

Q24645376-02284249-CBF0-4A1F-9119-2387626B1C46

Q24645376-0426E0DC-7BBA-48FF-BEA8-6B776F573771

Q24645376-08399399-529E-4251-B8BC-5AC158117BB8

Q24645376-11F7B164-D73F-47B2-BE15-FAD111D37089

Q24645376-1524F0B1-EE57-454A-8519-37ED6A2AE24B

Q24645376-28CDAE99-051E-4E2A-A906-666A20743CD8

Q24645376-2939FA20-7254-444C-8F8B-5EDAD8B4A9FE

Q24645376-2D37C540-F915-4EC2-BC16-8927D0D49077

Q24645376-3082C610-E6E0-4BEE-9738-106752C5C958

P304

Q24645376-DD823721-793E-4CDF-A787-03705D1B3017

P31

Q24645376-F2666D8E-A9FC-4DE0-BFD9-931CFCDABF5D

P3181

Q24645376-D7B508C5-56AD-4FD2-91C5-89BCAE7CA4E0

P356

Q24645376-45204A47-9EE8-4787-977E-4E9FA69C67B1

P407

Q24645376-086FB06F-D20B-4D70-B9D7-48B4A238F15F

P433

Q24645376-3C92BD1E-2AB6-4BEB-BD40-F7FCE42487B0

P478

Q24645376-DB893564-D21C-4855-9FBB-B69177719674

P50

Q24645376-6384D2FA-DFFC-4DCC-994F-58CACBB05A8A

P577

Q24645376-CB1B8C9E-619D-46F0-A9DF-5EE01E0F7C00

P5875

Q24645376-D51FA7A6-8787-4EE9-998B-7D8F308C2F81

P698

Q24645376-1C7E4A11-405A-4F0E-9EE8-AA77B98BE035

P921

Q24645376-9B8B9E58-1A49-45B5-B63E-118A5367B369

Q24645376-F2780BB4-6A11-4170-AF60-CACB75575C26

P932

Q24645376-48EFFCBF-DD34-432E-A1A9-86882E654E50

P3181

P356

P1433

European Heart Journal

P1476

Reductions in all-cause, cance ...... : a prospective registry study

@en

P2093

Andrew Neil

http://www.w3.org/2001/XMLSchema#string

Ian McDowell

http://www.w3.org/2001/XMLSchema#string

Jackie Cooper

http://www.w3.org/2001/XMLSchema#string

John Betteridge

http://www.w3.org/2001/XMLSchema#string

Mary Seed

http://www.w3.org/2001/XMLSchema#string

Nigel Capps

http://www.w3.org/2001/XMLSchema#string

Paul Durrington

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

Diagnosing familial hypercholesterolaemia: the relevance of genetic testing

Simvastatin with or without ezetimibe in familial hypercholesterolemia

Evaluation of methods for the measurement of low-density lipoprotein cholesterol.

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.

P304

2625-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1209857

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/EURHEARTJ/EHN422

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Stephen E Humphries

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23305274

http://www.w3.org/2001/XMLSchema#string

P698

18840879

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia

P932

2577142

http://www.w3.org/2001/XMLSchema#string